Merz Pharma Gmbh & Co Kgaa

Michael Althaus

Hagen Kruger

Nico Wegener

Janos Csikos

Barbara Ellers-Lenz

Irena Pulte

Tanja Rosenberg

Erhard Seiller

Markus Krueer

Markus Krüer

Hagen Krüger

Hagen Krueger

This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1.

Use of botulinum neurotoxin in the treatment of sialorrhea

The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.

1-aminocyclohexane derivatives for the treatment of cochlear tinnitus

The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus.

Titration package for neramexane and its use in the treatment of an inner ear disorder

Growing community of inventors

Osten, Germany

Michael Althaus